Last reviewed · How we verify

Clopidogrel reloading

University of Pecs · FDA-approved active Small molecule

Clopidogrel reloading involves administering a higher initial dose of clopidogrel to rapidly achieve platelet inhibition in acute coronary syndromes or percutaneous coronary intervention.

Clopidogrel reloading involves administering a higher initial dose of clopidogrel to rapidly achieve platelet inhibition in acute coronary syndromes or percutaneous coronary intervention. Used for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction, ST elevation myocardial infarction), Percutaneous coronary intervention with stent placement, Secondary prevention of atherothrombotic events.

At a glance

Generic nameClopidogrel reloading
Also known asClopidogrel = KARDOGREL
SponsorUniversity of Pecs
Drug classP2Y12 receptor antagonist / Thienopyridine antiplatelet agent
TargetP2Y12 receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation. A loading dose (typically 600 mg) is used to rapidly achieve therapeutic platelet inhibition levels, which is faster than maintenance dosing alone. This approach is particularly important in acute coronary syndromes and during percutaneous coronary intervention to reduce thrombotic events.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results